

# ForPatients

by Roche

Prostate Cancer Metastatic Prostate Cancer

## **Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer**

**Trial Status**  
Completed

**Trial Runs In**  
26 Countries

**Trial Identifier**  
NCT03072238 CO39303

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of ipatasertib plus abiraterone and prednisone/prednisolone compared with placebo plus abiraterone and prednisone/prednisolone in participants with metastatic castrate-resistant prostate cancer (mCRPC).

**Hoffmann-La Roche**  
Sponsor

**Phase 3**  
Phase

---

**NCT03072238 CO39303**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
Male

**Age**  
≥ 18 Years

**Healthy Volunteers**  
No

---